Adam Lauring, MD
Infectious Disease · Ann Arbor, MINPI 1215968169
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,205 of the $6,905 with a category attached, or 89.9%. 3 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 34.5% of the total. Reporting peaked in 2019 at $3,369 and has fallen 79.2% since, to $700 in 2024. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $767.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$2K
- F. Hoffmann-la Roche AG$2K
- Roche Products Limited$2K
Across 5 payments — averaging $22,498 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$112K
What the payments were for
- Consulting fees$6,20590%
- Speaking & faculty fees$6359%
- Food & beverage$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 2 | $2,381 |
| F. Hoffmann-la Roche AG | 4 | $2,314 |
| Roche Products Limited | 3 | $2,210 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofluza$2,419
- NO PRODUCT DISCUSSED$1,955
How this compares
$6,905 in reported general payments places this provider in the 90th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CeftriaxoneCeftriaxone Sodium | 34 | $911 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Ann Arbor
- Keith KayeAnn Arbor$187K
- Owen AlbinAnn Arbor$25K
- David MarkovitzAnn Arbor$24K
- Payal PatelAnn Arbor$23K
- Marisa MiceliAnn Arbor$19K
- Krishna RaoAnn Arbor$3K
- Laraine WasherAnn Arbor$3K
- Suzanne BradleyAnn Arbor$2K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.